A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer

  • Etude concernée: IFCT-2101
  • Auteurs / Authors: Duruisseaux M, Swalduz A, Mazieres J, Barlesi F, Amour E, Morin F, Westeel V
  • Journal / Conference: ASCO
  • Année / Year: 2022
  • PMID: Poster session
  • Lien vers la publication: https://meetings.asco.org/abstracts-presentations/213183